Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)

Inclusion Criteria: * Written informed consent for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures. * Complete baseline documentation must be submitted via the web-based data collection system MedCODES to the GBG Forschungs GmbH. * Diagnosis of locally advanced or metastatic hormone-sensitive or insensitive, HER2-negative or -positive breast cancer. * Relapse within ≤ 12 months after completing (last day of last cycle) (neo-) adjuvant chemotherapy. * Documented relapse of either a measurable or a non-measurable lesion according to the modified RECIST criteria. * Previous neoadjuvant or adjuvant treatment with a solvent based taxane (paclitaxel or docetaxel) irrespective of dose and duration. * Prior endocrine treatment for metastatic / advanced disease is allowed. * Complete radiological and clinical tumor assessment within 4 weeks prior to registration performed as clinically indicated. * Age ≥ 18 years. * ECOG Performance Status ≤ 2 (irrespective of restrictions due to breast cancer). * Laboratory requirements:Absolute neutrophil count (ANC) \>= 1.5 x 109/L., Platelets \>= 100 x 109/L., Hemoglobin \>= 9 g/dL (\>= 5.6 mmol/L)., Prothrombin time (PT) or international normalized ratio (INR) \<= 1.2x ULN (upper normal limit), Partial thromboplastin time (PTT) \<= 1.2x ULN, Total bilirubin \< 1.5x ULN, ASAT (SGOT) and ALAT (SGPT) \<= 2.5x ULN (concomitant elevations in serum bilirubin and ASAT/ALAT above 1.0x ULN a…